Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Pacira Biosciences Inc.

Headquarters: Parsippany, NJ, United States of America
Year Founded: 2007
Status: Public
Industry Sector: HealthTechnology
CEO: Frank D. Lee, MBA
Number Of Employees: 790
Enterprise Value: $1,025,493,800
PE Ratio: -10.3
Exchange/Ticker 1: NASDAQ:PCRX
Exchange/Ticker 2: N/A
Latest Market Cap: $1,050,006,976

BioCentury | Jan 23, 2025
Management Tracks

New COOs for Vividion, Edgewise

Plus: Pacira names new heads of commercial, CBO and updates from Vib spinout Tanai, Arcus, Kyverna and Alx 
BioCentury | Dec 23, 2023
Management Tracks

Pacira names Lee CEO, Hastings chair

Plus: CRISPR’s CMO to depart and a new CFO for Alterity
BioCentury | Sep 27, 2023
Management Tracks

Morphic CEO Tipirneni taking medical leave of absence

Plus: David Stack to retire as chair, CEO of Pacira and updates from AM-Pharma, Invitae, Syneos and Faeth 
BioCentury | Jul 19, 2022
Management Tracks

Sanofi’s Mei becomes CMO at Editas

Plus Ullmann to retire from J&J, and updates from Rome, Nuvation, Evelo and more
BioCentury | May 11, 2022
Product Development

May 10 Quick Takes: ‘molecular machines’ company MOMA lands $150M series B

Plus GPCR play Domain raises $42M and updates from OncoHost, Eisai, UCB, Idorsia and more
BioCentury | Jan 27, 2022
Management Tracks

Adaptimmune hires Piccina as CCO as it readies for first BLA

Plus Rowe new CSO at Cystic Fibrosis Foundation and updates from Immunovant, Senda, F2G and more
BioCentury | Jan 3, 2022
Product Development

What’s next for voltage-gated sodium channel blockers

Companies dial in subtype selectivity, explore new modalities, and move to more homogeneous trial populations
BioCentury | Oct 12, 2021
Finance

4Q financial markets preview, plus the future of NIH

Plus Novartis CEO’s view of translational science and this week’s Deal in Focus, Flexion-Pacira
BioCentury | Oct 11, 2021
Deals

With CVR, Pacira’s deal for Flexion could nearly double in size

Analgesics company Pacira adds marketed osteoarthritis therapy, with more upside for Flexion shareholders
BioCentury | Aug 3, 2021
Product Development

Ten PDUFA dates on deck in August: Data Byte

At least ten therapies have PDUFA dates this month, seven of which have been granted priority review by FDA.  The agency is expected to announce its first two decisions on Friday for an NDA for
Items per page:
1 - 10 of 23